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Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of
hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with vori-
conazole (20 samples in 13 patients) as well as in plasma samples from ICU patients that had been spiked with voriconazole at
concentrations of 1.5 mg/liter, 2.9 mg/liter, and 9.0 mg/liter (66 samples from 22 patients). Plasma albumin concentrations
ranged from 13.8 to 38.7 g/liter. Total voriconazole concentrations in adult ICU patients treated with voriconazole ranged from
0.5 to 8.7 mg/liter. Unbound and bound voriconazole concentrations were separated using high-throughput equilibrium dialysis
followed by liquid chromatography-tandemmass spectrometry (LC-MSMS). Multivariate analysis revealed a positive relation-
ship between voriconazole plasma protein binding and plasma albumin concentrations (P< 0.001), indicating higher unbound
voriconazole concentrations with decreasing albumin concentrations. The correlation is more pronounced in the presence of
elevated bilirubin concentrations (P 0.05). We therefore propose to adjust the measured total voriconazole concentrations in
patients with abnormal plasma albumin and total serum bilirubin plasma concentrations who show adverse events potentially
related to voriconazole via a formula that we developed. Assuming 50% protein binding on average and an upper limit of 5.5
mg/liter for total voriconazole concentrations, the upper limit for unbound voriconazole concentrations is 2.75 mg/liter. Altera-
tions in voriconazole unbound concentrations caused by hypoalbuminemia and/or elevated bilirubin plasma concentrations
cannot be countered immediately, due to the adult saturated hepatic metabolism. Consequently, increased unbound voricona-
zole concentrations can possibly cause adverse events, even when total voriconazole concentrations are within the reference
range.
Setting an adequate dosing regimen for voriconazole remainschallenging given the nonlinear pharmacokinetic profile in
adults (1). The extreme intra- and interpatient variability in
plasma concentrations in the context of established exposure-
response/toxicity relationships has triggered the need for thera-
peutic drug monitoring (TDM) in daily practice (1–4). Extensive
pharmacokinetic research has revealed several altering covariates,
including CYP450-mediated drug-drug interactions (5), genetic
polymorphism associated with the CYP2C19 enzyme (6), age (7–
9), liver disease (10), coadministration of drug with food (11, 12)
or enteral feeding (13), and switching from intravenous to oral
administration (1, 14). As a result, inadequate responses or severe
toxic events have been reported.
Recently, plasma protein binding (PPB) has been investigated
as an additional factor influencing the pharmacokinetics (PK) of
antimicrobial agents (15–18). Since hypoalbuminemia occurs in
approximately 40% of critically ill patients (18), the potentially
negative effects of altered protein binding of antimicrobials may
be common (19, 20). Unbound drug concentrations can differ
among patients and underlying disorders, resulting in different
responses to therapy or toxicity, as only the unbound drug con-
centration exhibits pharmacological activity (21). Hypoalbumin-
emia usually results in higher unbound drug concentrations in
plasma (16). Because the temporary increase in the unbound
plasma concentration is reversed by the rapid distribution and
elimination of the drug via the liver or the kidneys, this phenom-
enon is expected to be clinically relevant only for highly protein-
bound drugs (PPB above 70%) (16). However, for drugs such as
voriconazole, with nonlinear pharmacokinetics (6–8), the ele-
vated unbound drug concentration in plasma caused by decreased
plasma albumin concentrations cannot be instantly metabolized
and eliminated. This can be explained by its saturatedmetabolism
and the fact that only 2%of voriconazole is excreted unchanged in
urine (22). Although voriconazole PPB is only 50% (23), this
saturated metabolism is hypothesized to cause clinically relevant
variations in unbound fractions in cases of hypoalbuminemia,
potentially resulting in an increased risk for toxic adverse events,
evenwith a total voriconazole trough concentration (VTC)within
the reference range of 1 or 2 up to 5.5 mg/liter (24–26).
In the past, equationswere developed to correctmeasured total
concentrations of antiepileptics in the function of the higher free
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fraction in cases of hypoalbuminemia. These formulae are applied
in daily clinical practice, the formula for valproic acid being the
Hermida Tutor formula (27) and that for phenytoin being the
Sheiner Tozer orWinter-Tozer formula (28, 29), as both drugs are
characterized by high PPB and saturated metabolism. This ren-
ders patients with hypoalbuminemia prone to toxicity even with
total measured concentrations within the reference interval (30).
In this study, the potential influence of hypoalbuminemia on
voriconazole pharmacokinetics, which has thus far not been ad-
dressed in detail, was investigated.
MATERIALS AND METHODS
Patient inclusion.A prospective PK study (study A) was conducted at the
University Hospitals Leuven from July 2012 until August 2013 to assess
PPB of voriconazole in medical intensive care unit (ICU) patients. Con-
secutive patients admitted to the 17-bed medical ICU and with at least 4
consecutive days of voriconazole treatment (Vfend; Pfizer Belgium) for
invasive aspergillosis (IA) were eligible (31). Only patients with a docu-
mented total VTC of at least 0.4mg/liter were eligible, as the lower limit of
quantification (LLOQ) of our in-house validated liquid-chromatogra-
phy–tandemmass spectrometry (LC-MSMS) method (32) used to quan-
tify voriconazole concentrations is 0.2mg/liter (32) and PPB is about 50%
in patients without hypoalbuminemia, as previously reported by our
group (23).
At the same time, we conducted an in vitro study (study B) in which
plasma samples from ICU patients without IA but with plasma albumin
concentrations ranging from 10 to 35 g/liter (reference range, 35 to 52
g/liter) were spiked with voriconazole, resulting in 3 final concentrations
(5 M, 10 M, and 30 M, corresponding to 1.5 mg/liter, 2.9 mg/liter,
and 9.0 mg/liter). Plasma albumin concentrations were determined with
colorimetry using bromocresol green (33). Both studies were conducted
in accordance with the Declaration of Helsinki. Approval from the local
Ethical Committee and written informed consent from each subject were
obtained.
High-throughput equilibrium dialysis followed by LC-MSMS. All
heparinized blood samples from study A and study B patients were cen-
trifuged (10min, 1,500 g, 20°C) immediately after sampling through an
arterial catheter, and plasma was stored at20°C until analysis. In study
B, spiking with voriconazole was carried out in batch just before equilib-
rium dialysis. Unbound and bound fractions of voriconazole were sepa-
rated using high-throughput equilibrium dialysis (HT-ED), as described
elsewhere (23). HT-ED is a robust method to separate unbound and
bound voriconazole concentrations without an impact of environmental
temperature, frozen storage, freeze-thaw cycles, and total voriconazole
concentrations. Mass balance was checked, and no volume shift was ob-
served. Voriconazole PPBwas determined in 235 samples of blank plasma
spiked with voriconazole, resulting in amedian PPB of 47.6% (interquar-
tile range [IQR], 45.3% to 50%). More importantly, these results were
compared with the PPB of voriconazole measured in plasma from criti-
cally ill patients (20 samples from 13 patients) treated with voriconazole,
resulting in a median PPB of 49.6% (IQR, 42.5% to 52.5%) (P 0.35).
In brief, plasma was separated from phosphate-buffered saline (PBS)
in a 96-well plate with a semipermeable membrane (molecular weight
cutoff [WMCO], 12 to 14) through which unbound voriconazole can
permeate. Equilibriumwas reached after 4 h at 37°C. After reaching equi-
librium, voriconazole concentrations in both the plasma and the buffer
compartment were determined using a validated LC-MSMSmethod (32),
with a LLOQ of 0.2 mg/liter, between-run precision, expressed as coeffi-
cient of variation, below 12%, and accuracy, expressed as a percentage of
the theoretically added concentration, of between 89% and 109%. Linear-
ity from 0.06 to 20.0 mg/liter was demonstrated.
The percentage of unbound voriconazole was calculated as follows
(34):
UF%
[voriconazole]PBS
[voriconazole]plasma
 100 (1)
whereUF% stands for the percentage of unbound voriconazole and [vori-
conazole]PBS and [voriconazole]plasma represent the concentrations of
voriconazole at equilibrium in the buffer compartment and in the plasma
compartment, respectively.
Data collection. Baseline data in the following categories were col-
lected from the patient’s electronic medical records and from the labora-
tory records: age, gender, weight, acute physiology and chronic health
evaluation II (APACHE II) score at admission, underlying condition, di-
agnosis upon admission, in-hospital mortality, and 28-day mortality (de-
fined as mortality within 28 days after discharge from the ICU). Treat-
ment details consisted of the voriconazole daily dose and route of
administration and coadministered drugs at the day of sampling, with
special focus on those with high (above 70%) PPB, such as vitamin K
antagonists, aspirin, nonsteroid anti-inflammatory drugs (NSAIDs), phe-
nytoin, and valproic acid (35). Biochemical findings on the day of sam-
pling included C-reactive protein (CRP) concentrations, albumin and
-1-acid glycoprotein (AAG) plasma concentrations, total plasma pro-
tein concentrations, blood urea nitrogen, creatinine plasma concentra-
tions, creatinine clearance (Chronic Kidney Disease-Epidemiology Col-
laboration [CKD-EPI]), total and direct bilirubin plasma concentrations,
and total VTCs. Also, liver function tests (plasma concentrations of ala-
nine transaminase [ALT], aspartate transaminase [AST], bilirubin, gam-
ma-glutamyltransferase [GT], and alkaline phosphatase) were per-
formed to detect abnormalities possibly caused by voriconazole. Any type
of neurological adverse events was also monitored.
Statistical analysis. Statistical analysis was performed using SPSS 20.0
for Windows (SPSS Inc. 2011, Chicago, IL). P 	 0.05 was considered
significant. Data were described with means standard deviations (SD)
or medians and IQR according to the data distribution. Univariate corre-
lations were investigated using scatterplots combined with Spearman’s
rank correlation coefficients. Multivariate analysis was conducted using
linear mixedmodels with random intercept. Spearman’s rank correlation
coefficients were used instead of Pearson correlation coefficients because
no assumptions of linearity were made in advance. However, because
linear mixed models were used to create the prediction formula, Pearson
correlation coefficients could also be used in this analysis.
RESULTS
Table 1 displays the baseline demographic and clinical and bio-
chemical data for all patients included in both studies. In study A,
20 plasma samples were obtained from 13 patients. All patients
received voriconazole for the treatment of IA (11 cases of probable
and 2 cases of possible IA according to the revised criteria of the
European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
[EORTC/MSG]) (31). Risk factors for IA included the following:
high-dose corticosteroids for chronic obstructive lung disorders
(n 5), lung transplantation (n 1), radiotherapy for bronchus
carcinoma (n 1), kidney transplantation (n 2), acutemyeloid
leukemia (n  2), multiple organ failure following pancreatitis
(n  1), and vasculitis treated with immunosuppressive therapy
(n 1). In the in vitro study (study B), 66 plasma samples from 22
patients without aspergillosis were used. Plasma albumin levels
ranged from 10 to 14.9 g/liter (2 patients), 15 to 19.9 g/liter (5
patients), 20 to 24.9 g/liter (5 patients), 25 to 29.9 g/liter (5 pa-
tients), and 30 to 35 g/liter (5 patients).
Voriconazole PPB correlated stronglywith the plasma albumin
concentration in the univariate analysis (for study A, R  0.61,
P	 0.01; for study B, R 0.71, P	 0.01; for the combined data
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set, R  0.67, P 	 0.01) as shown in Fig. 1. No correlations and
weak or moderate correlations with total bilirubin plasma con-
centration were seen in the univariate analysis (for study A, R 
0.17, P 0.49; for study B, R0.42, P	 0.01; for the com-
bined data set, R039, P	 0.01) or for age (for study A, R
0.01, P  0.966; for study B, R  0.09, P 	 0.49; for the
combined data set, R  0.10, P  0.36), AAG plasma concen-
tration (for study A, R 0.049, P 0.838; for study B, R 0.27,
P 0.03; for the combined data set,R 0.23, P 0.03), CRP (for
study A, R0.27, P 0.251; for study B, R0.09, P	 0.45;
for the combined data set, R  0.15, P  0.17), and total VTC
(for study A, R  0.40, P  0.09; for study B, R  0.04, P 
0.77; for the combined data set, R  0.12, P  0.26). Pearson
correlation coefficients were very similar to the Spearman’s rank
correlation coefficients (data not shown).
A multiple linear mixed model using the combined data set
from study A and study B provided the following results: vori-
conazole PPB was influenced by plasma albumin concentrations
(P 	 0.001) and total bilirubin concentrations (P  0.04). The
number of drugs with a PPB higher than 70%did not significantly
influence the final PPB of voriconazole (P 0.36). According to
our model, voriconazole PPB decreases by 0.67% if the plasma
albumin concentration decreases by 1 g/liter (P	 0.001) and total
bilirubin concentrations remain stable. An increase of 1 mg/dl in
the total bilirubin concentration with stable plasma albumin con-
centrations results in a decrease in PPB of 0.19% (P	 0.001).
Based on these results, the bound voriconazole fraction can be
predicted with the following equations:
VRC PPB 30.5015 0.668HPA 0.1867 Bilitot
(2)
Adjusted total VTC

(100 VRC PPB)
100
measured total VTC 2 (3)
where VRC PPB is the percentage of voriconazole protein binding,
total VTC represents the total voriconazole trough level expressed in
mg/liter, HPA represents the human plasma albumin concentration
expressed in g/liter, and Bilitot represents the total bilirubin plasma
concentration expressed in mg/dl. Assuming that the level of vori-
conazole PPB is 50% (23) on average and assuming an upper limit of
5.5mg/liter (26) for total VTCs associatedwith a relatively low prob-
TABLE 1 Demographics and clinical and biochemical characteristics at day of sampling of patients treated with voriconazole and patients with
hypoalbuminemia not treated with voriconazole whose plasma samples were spiked with voriconazole
Demographic or characteristic
Value(s) or resulta
Study A Study B Total
Demographics
No. of patients 13 22 35
Median [IQR] age (yrs) 62 [57.5–71.5] 66 [60–74] 65 [58–73]
Median [IQR] wt (kg) 68 [61–82.5] 71 [60.3–80] 68 [62–80]
No. (%) of males 7 (53.8) 14 (63.6) 21 (60)
Mean APACHE II score SD 26.8 6.9 23.5 10.0 25.3 8.3
No. (%) of cases of in-hospital mortality 6 (46.2) 9 (40.9) 15 (42.9)
No. (%) of cases of 28-day mortality 6 (46.2) 8 (36.4) 15 (42.9)
Clinical and biochemical characteristics
Total no. of samples 20 66 86
No. (%) of samples from patients with i.v. VRC administrationb 20 (100) Not applicable Not applicable
Median [range] albumin plasma concn (g/liter) (35–52)b,e 31.1 [13.8–38.7] 23.7 [14.4–33.7] 26.7 [13.8–38.7]
Median [range] AAG plasma concn (g/liter) (0.51–1.17)b,e 1.8 [1.1–3.0] 1.4 [0–2.4] 1.47 [0–3.0]
Mean total plasma protein concn SD (g/liter) (66–87)b,e 56.6 7.3 (n 18) 53.4 12.4 (n 63) 54.2 11.5
Median [IQR] total bilirubin plasma concn (mg/liter) (	1)b,e 0.41 [0.28–1.69] (n 12) 0.75 [0.42–1.93] 0.67 [0.42–1.80] (n 85)
Median [IQR] blood urea nitrogen (mg/dl) (	50)b,e 70 [44.8–112.5] 54.5[37–146] 57.5 [37–132.5]
Median [IQR] creatinine plasma concn (mg/dl) (F, 0.51–0.95;
M, 0.67–1.17)b,e
0.95 [0.52–1.57] 1.14 [0.67–1.99] (n 57) 1.13 [0.67–1.81] (n 77)
CKD-EPI eGFR [ml/(min 1.73m2)]b 84 [37.5–108.3] 66 [40–93] 74 [40–100]
Median [IQR] CRP plasma concn (mg/liter) (	5)b,e 47.2 [21.6–116.9] 72.1 [48.2–89.6] 71.5 [30.8–92.5]
Median [IQR] VRC daily dose (mg/day)b 580 [465–800] Not applicable Not applicable
Median [IQR] VRC daily dose (mg/kg/day)b 8 [7.5–8.3] Not applicable Not applicable
Median [IQR] no. of days of VRC treatment at day of sampling 6 [4–13] Not applicable Not applicable
Median [IQR] total VRC plasma concn (mg/liter)b 2.4 [1.5–4.5] 1.5; 2.9; 9.0 (spiking expt) 2.9 [1.5–9.0]
Median [IQR] unbound VRC plasma concn (mg/liter) 0.71 [0.51–1.46] 0.86 [0.45–2.66] 0.85 [0.46–2.55]
Median [IQR] bound VRC plasma concn (mg/liter) 1.52 [1.07–2.57] 1.63 [0.85–5.35] 1.62 [0.87–5.07]
Median [IQR] % protein binding 49.6 [42.5–52.5] 49.1 [42.6–52.3] 49.1 [42.6–52.4]
Median [IQR] no. of coadministered drugs with PPB
 70%b 2.5 [2–3]c 4.5 [1–6]d 3 [2–5]
a Study A, patients admitted to the ICU and treated with voriconazole; study B, patients admitted to the ICU and not treated with voriconazole (plasma spiked with 1.5, 2.9, and 9
mg/liter). i.v., intravenous; eGFR, estimated glomerular filtration rate; VRC, voriconazole; CRP, C-reactive protein; AAG, -1-acid glycoprotein; n, number of samples.
b Day of sampling.
c In study A, no coadministration of NSAIDs, phenytoin, valproic acid, coumarins, or aspirin was documented.
d In study B, administration of aspirin was documented in 7 patients and of acenocoumarol and phenytoin in 1 patient each. No coadministration of NSAIDs or valproic acid was
documented.
e The values in parentheses represent reference values according to the University Hospitals Leuven.
Vanstraelen et al.
6784 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 11, 2014 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
abilityof toxicity, theupper limit fornontoxicunboundvoriconazole
concentrations is 2.75mg/liter. These assumptions, togetherwith the
above-mentioned formula, resulted in the data presented in Fig. 2, in
which the clinical applicability of our proposed formula is demon-
strated for two values of total bilirubin plasma concentrations and a
broad range of measured VTCs.
DISCUSSION
To the best of our knowledge, this is the first report to show a
positive correlation between voriconazole PPB and plasma albu-
min concentration (P	 0.001).
Apart from the plasma albumin concentration, the total bili-
rubin plasma concentration also influences voriconazole PPB sig-
nificantly (P  0.04), probably because it is largely (up to 90%)
protein bound, causing displacement of drugs from albumin (36).
We present a formula to adjust measured VTCs in individual
cases, based on plasma albumin and total bilirubin concentra-
tions. Similar formulas were developed previously to estimate un-
bound concentrations of phenytoin and valproic acid, two anti-
epileptic drugs with high PPB (above 70%) based on plasma
albumin concentrations (27, 28), as total measured plasma con-
centrations could not always explain adverse events seen in pa-
tients (37–41).
Although the total bilirubin plasma concentration is included
in the formula, Fig. 2 shows that it mainly influences voriconazole
PPB in the case of total bilirubin plasma concentrations above 5
mg/dl. A statistically significant correlation between voriconazole
PPB and total bilirubin concentrations was found in themultivar-
iate analysis of the combined data set, but the correlation disap-
peared with total bilirubin concentrations above 5 mg/dl (P 
0.32; data not shown). Despite the warning not to use voricona-
zole in cases of Child-Pugh C liver cirrhosis with bilirubin plasma
concentrations above 3 mg/liter (Vfend labeling [http://labeling
.pfizer.com/ShowLabeling.aspx?id618]), higher bilirubin con-
centrations are often seen in ICU patients in situations of acute
disease, including patients with severe sepsis, ischemic hepatitis,
or bile duct obstruction (42). The exact impact of bilirubin on
voriconazole PPB should be further confirmed, e.g., by in vitro
spiking experiments using plasma from patients with different
plasma albumin and total bilirubin plasma concentrations.
We believe that our hypothesis and formula are clinically rele-
vant. First, measured total VTCs should be interpreted with cau-
tion with regard to the reference range, especially in patients with
profound hypoalbuminemia and total VTCs close to the upper
limit of the therapeutic reference range. Dose adjustments should
be considered and our proposed formula should be applied for
patients with adverse events potentially related to an increased
unbound voriconazole plasma concentration. In our center, we
selected 2 to 5.5 mg/liter as the reference range for total VTCs
(24–26, 43, 44). However, as there is still no clear consensus about
the reference range of VTCs (24–26, 43, 45–49), the same conclu-
sions can be drawn when simulating the worst-case scenario with
an upper limit of 4 mg/liter (45–48), as shown in Fig. 2. Second,
one could question whether free drug monitoring for voricona-
zole should be implemented in daily practice in a manner compa-
rable to what has recently been discussed for vancomycin (50).
However, the most important issue for voriconazole administra-
tion is to avoid subtherapeutic VTCs and therapeutic failure, es-
pecially in a Caucasian population most often presenting with
wild-type CYP2C9/CYP2C19 metabolism, rather than to avoid
toxicity associated with supratherapeutic VTCs (51). Therefore,
this process would be too time-consuming, due to an additional
step of, e.g., equilibrium dialysis or other separating techniques
which should be built in the analytical process (23), making our
proposed formula more practical to use. Still, our findings are
definitely relevant, because even if few patients would suffer from
adverse events due to increased elevated unbound voriconazole
concentrations, it would be beneficial to prevent therapy cessation
or to indicate a need to switch to another antifungal agent. More-
over, in other populations in which toxicity is the main driver of
therapeutic drug monitoring, as described for a Korean random-
ized controlled trial (52), adjustingmeasured total VTCs based on
plasma albumin concentrations might avoid hepato- and neuro-
toxicity, being the most common side effects requiring a switch to
an alternative antifungal therapy. It is possible that neurotoxicity
can occur in patients with hypoalbuminemia and total VTCs
within the reference range because of the increased unbound vori-
conazole concentration which can penetrate the blood-brain bar-
rier. Otherwise, higher penetration of increased unbound vori-
conazole concentrations through the blood-brain barrier could
also improve the therapeutic effect in cases of an invasive fungal
infection in the central nervous system. Third, given the extremely
variable pharmacokinetic profile of voriconazole, the discovery of
additional PK-altering factors may be of great value in unraveling
the rather unpredictable behavior of voriconazole in the human
body. Finally, conflicting information has been published in the
past about the clinical relevance of increased unbound drug con-
centrations in cases of hypoalbuminemia (30, 53). However, in
these studies, the drugs that were the subject of debateweremostly
drugs with linear pharmacokinetics. The influence of hypoalbu-
minemia on protein binding characteristics of antimicrobial
agents was demonstrated in critically ill patients (15, 16) for highly
FIG 1 Positive correlation between the percentages of voriconazole plasma
protein binding (PPB) and plasma albumin concentrations (in grams/liter)
according to the univariate analysis of the combined set of data from study
A (patients admitted to the ICU and treated with voriconazole) and study
B (patients admitted to the ICU and not treated with voriconazole; plasma
spiked with 1.5, 2.9, and 9 mg/liter voriconazole).
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protein-bound drugs (PPB above 70%) (16) such as ceftriaxone
(PPB,95%) (19), flucloxacilline (PPB, above 90%) (15), carba-
mazepine (PPB, 70% to 80%) (54), phenytoin (PPB,90%) (28,
55, 56), and valproic acid (PPB, 80% to 90%) (27, 57). For drugs
with low tomoderate PPB (30 to 70%) and linear pharmacokinet-
ics, changes in PPB have little consequence in clinical practice, as
small increases in unbound drug concentrations are immediately
metabolized and eliminated (16). To the best of our knowledge,
we are the first to show the influence of hypoalbuminemia on the
PPB of voriconazole, a drug with a nonlinear PK profile due to a
saturated metabolism combined with a narrow therapeutic range
and moderate PPB. Recently, unbound voriconazole concentra-
tions were also investigated with ultrafiltration (UF) by Florent et
al. A correlationwas seen between the unbound voriconazole frac-
tion and albumin plasma concentrations below 25 g/liter. Overall,
no clear correlation with plasma albumin concentrations was
measurable (58). Remarkably, the voriconazole PPB values were
highly deviant from our previously published in vitro data, from
the data published by Roffey et al. (59), and from the results in this
study, whichwere all generated by ED, in our opinion still the gold
standard in determining protein binding of drugs (34, 60–62).
Moreover, the most important factors possibly influencing the
performance of the EDprocedure, such as environmental temper-
ature, pH, mass balance, and volume shift, were ruled out (23),
resulting in a robust and reliable method for determining vori-
conazole PPB. We believe that the differences in PPB might po-
tentially be explained by the use of different methods for the sep-
aration of unbound and bound voriconazole concentrations. It
has previously been shown that UF may underestimate unbound
drug concentrations compared to ED (63).
Although highly protein-bound drugs are able to expel other
drugs from albumin, thereby inducing elevated unbound plasma
concentrations (64), no significant correlation between voricona-
zole PPB and the amount of coadministered drugs with a PPB of
more than 70% could be found in our study population. Apart
from a high PPB, drugs should have affinity for the same albumin
binding places to expel voriconazole from the plasma protein
(65). In study A, none of the included patients received nonsteroi-
dal anti-inflammatory drugs (NSAIDs) (PPB above 90%), aspirin
(PPB above 99%), phenytoin (PPB of90%) (66), valproic acid
(PPB of 80% to 90%) (67), or vitamin K antagonists (PPB above
90%), drugs especially known for their ability to expel drugs from
albumin (35). In study B, 7 patients received aspirin, and only 1
patient received the vitamin K antagonist acenocoumarol. The
role of coadministration of these specific highly protein-bound
drugs in voriconazole PPB should be elucidated in the future both
FIG 2 Adjusted total voriconazole trough concentrations (VTCs) based on plasma albumin concentrations (HPA), total bilirubin plasma concentrations
(Bilitot), and measured VTCs. VTC  total voriconazole trough concentration (mg/liter). Adjusted VTCs were calculated with the following formula:
adjusted VTC [(100 VRC PPB)/100]measured VTC 2 (where VRC PPB 30.5015 0.668HPA 0.1867 Bilitot, based on the multivariate
analysis of the combined data set of plasma from ICU patients treated with VRC and plasma from ICU patients not treated with VRC, spiked with 1.5, 2.9,
and 9mg/liter of VRC. Solid diagonal lines represent adjusted VTCs for measured VTCs ranging from 3.5 to 6 mg/liter, when Bilitot equals 1 mg/dl. Dotted
diagonal lines represent adjusted VTCs for measured VTCs ranging from 3.5 to 6 mg/liter, when Bilitot equals 10 mg/dl. Solid horizontal line A represents
an upper limit of 5.5 mg/liter for total VTCs associated with a relatively low probability of toxicity. Dashed horizontal line B represents an upper limit of
4 mg/liter for total VTCs associated with a relatively low probability of toxicity. VRC, voriconazole.
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in a real-life setting and in in vitro spiking experiments with vori-
conazole and albumin and known concentrations of the displac-
ing agents.
The most important limitation of this experiment was the rel-
atively small data set. However, to our knowledge, this is the first
report identifying the role of protein binding and hypoalbumin-
emia in the variable PK profile of voriconazole, and as the corre-
lation was already clearly significant in our rather limited data set,
we believe that larger data sets would only confirm this. A pro-
spective experiment in which plasma albumin concentrations and
unbound voriconazole plasma concentrations are closely moni-
tored in all patients treated with voriconazole, suffering from ad-
verse events due to voriconazole, irrespective of the total VTCs,
would be interesting to document the clinical relevance.
The fact that we combined real-life samples with spiked plasma
is not really a limitation. No significant differences between the
PPB values of the two groups were found, a result which had
already been shown in our previous work (23).Moreover, all sam-
ples were taken in a medical ICU population and were subject to
identical sample handling procedures. Premarketing studies de-
termining the PPB characteristics of drugs are often similarly per-
formed on blank plasma spikedwith the investigational drug (59).
Only adult ICU patients were included in this study. Most
likely, this phenomenon will also be seen in adult non-critically ill
patients presenting with severe hypoalbuminemia treated with
voriconazole. Apart from plasma albumin and total bilirubin
plasma concentrations, no additional factors influencing vori-
conazole PPB, specifically associated with or encountered in ICU
patients, were identified in the multivariate analysis. It would be
interesting to confirmour results in, e.g., a cohort of non-critically
ill patients with hematological disease. In the pediatric popula-
tion, we do not expect a clinically relevant influence of hypoalbu-
minemia on voriconazole PPB. Similarly to drugs with linear
pharmacokinetics and moderate to low protein binding, elevated
unbound concentrations due to hypoalbuminemia would proba-
bly be quickly metabolized and cleared due to the additional ac-
tivity of the flavin-containingmono-oxygenase 3 (FMO3) enzyme
system, responsible for the linear voriconazole pharmacokinetics
in children, within the reference range (7, 8).
Finally, no data are available for plasma albumin concentra-
tions above 40 g/liter. However, because hyperalbuminemia with
values above 50 g/liter is not often seen in clinical practice, we do
not expect large differences from the adjusted total voriconazole
concentrations in the case of albumin concentrations just below
40 g/liter.
Conclusion. Although voriconazole PPB is documented to be
moderate (50%) in patients with normal plasma albumin levels,
hypoalbuminemia can alter voriconazole PPB, probably due to
the saturated hepatic metabolism. Increased unbound voricona-
zole plasma concentrations in patients with profound hypoalbu-
minemia can possibly cause adverse events, even when total vori-
conazole plasma concentrations are within the reference range.
Likewise, measured total voriconazole concentrations should be
adjusted via the proposed formula, in patients suffering from hy-
poalbuminemia and showing adverse events potentially related to
voriconazole, especially in those with severe hypoalbuminemia.
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